> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aspen Neuroscience Sets $15-$17 Range for IPO as Auditors' Doubt Over Its Survival Persists
- URL: https://www.bullished.co/aspen-neuroscience-sets-15-17-range-for-ipo-as-auditors-doubt-over-its-survival-persists-a06ead75/
- Published: 2026-10-26T11:11:56.000Z
- Updated: 2026-11-05T20:17:09.000Z
- Description: The cell-therapy developer proposes 9,375,000 shares on Nasdaq under ASPE after a reverse stock split, with about $72.4 million in cash at June 30.
- Author: Matteo Parrino
- Tags: Deals, Industry: Not classified

Aspen Neuroscience, a San Diego clinical-stage company developing a cell therapy for Parkinson's disease, set a proposed price range of $15.00 to $17.00 a share for [9,375,000 shares](https://www.sec.gov/Archives/edgar/data/0002124080/000119312526431023/na-20261026.htm?ref=bullished.co) in an amended IPO filing on Monday. The filing keeps the warning that its finances raise "substantial doubt" about its ability to continue as a going concern.

## The offering terms

Aspen has applied to list on the Nasdaq Global Select Market under the symbol ASPE. Underwriters hold a 30-day option to buy up to [1,406,250 more shares](https://www.sec.gov/Archives/edgar/data/0002124080/000119312526431023/na-20261026.htm?ref=bullished.co). The lead banks are Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel and Oppenheimer.

At the $16.00 midpoint, the company estimates net proceeds of about $134.5 million, or about $155.4 million if the option is exercised in full. It expects 29,078,600 shares outstanding after the offering, or 30,484,850 with the option. The count reflects a 1-for-9.8821 reverse stock split effected on October 23, 2026, plus the conversion of its preferred stock into common.

## Cash, losses and the going-concern warning

Aspen held $72.4 million in cash, cash equivalents and marketable securities at June 30, 2026\. It lost $36.5 million in the first six months of 2026, against $31.8 million a year earlier, and $62.1 million in all of 2025\. Its accumulated deficit stood at $264.9 million.

The company says that cash alone will not cover operations for the 12 months after its financial statements were issued, so it concluded that substantial doubt exists. It says the IPO proceeds plus existing cash would fund operations into the second half of 2028, but it will need substantial additional capital even if the offering succeeds.

The company plans to spend about $110.0 million of proceeds on a Phase 3 trial of sasineprocel, about $8.0 million on the ongoing early-to-mid-stage ASPIRO trial and about $4.0 million on its microglia programs.

## A Parkinson's therapy from a patient's own cells

Sasineprocel is made from a patient's own skin cells, reprogrammed into stem cells and then turned into precursors of the dopamine neurons Parkinson's destroys. Founded in 2018, Aspen says it has raised about $347 million from investors including OrbiMed, ARCH Venture Partners and Kite, a Gilead Company.

As of August 18, 2026, 15 patients had been dosed in ASPIRO. The company says it saw sustained improvements in motor and quality-of-life measures. The trial is open-label, with no placebo or control group, and the filing warns such designs can exaggerate results. Aspen expects to include a control group in Phase 3.

It anticipates starting biopsy collection for Phase 3 by the end of 2026 and dosing patients in the second half of 2027.

Pricing, and the first Nasdaq trades under ASPE, are the next steps; the company says it plans to start Phase 3 biopsy collection by the end of 2026.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [S-1/A — Aspen Neuroscience, Inc.](https://www.sec.gov/Archives/edgar/data/0002124080/000119312526431023/na-20261026.htm?ref=bullished.co) — SEC EDGAR